Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2022-01-26 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
监事会关于公司2022年度向特定对象发行股票的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written audit opinion from the Supervisory Board regarding the company's 2022 issuance of shares to specific investors. It references compliance with company law, securities law, and stock exchange listing rules, and discusses the feasibility and fairness of the share issuance plan. The document is short (1200 characters) and is an official announcement of the Supervisory Board's approval and opinion on the share issuance. It does not contain financial statements or detailed financial data, nor is it a full report like an annual or interim report. It is not a certification letter or a voting result announcement. The content fits best with a Capital/Financing Update (CAP) as it relates to a specific financing activity (share issuance to specific investors).
2022-01-26 Chinese
关于向北京景达生物科技有限公司投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding its investment in Beijing Jingda Biotechnology Co., Ltd. It details the investment amount, shareholding percentage, the nature of the investment, the company's board meeting resolutions approving the investment, and the impact and risks associated with the investment. The document includes financial data of the target company and the investor but does not contain comprehensive financial statements or detailed financial performance analysis of the reporting company itself. It is not an annual or interim report, earnings release, or audit report. It is a regulatory announcement about a capital investment transaction, specifically an investment in another company, which affects the company's capital structure and business operations. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (7692 characters) and detailed content support this classification with high confidence.
2022-01-26 Chinese
2022年度向特定对象发行股票方案可行性论证分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled '2022 年度向特定对象发行股票方案 可行性论证分析报告（修订稿）' which translates to '2022 Annual Feasibility Analysis Report on Private Placement of Shares to Specific Objects (Revised Draft)'. It discusses the company's plan to issue shares to specific investors, including details on the background, purpose, pricing, legal compliance, and impact on earnings per share. The document is a detailed feasibility and analysis report related to a capital raising activity through a private placement of shares. It is not an announcement of the issuance, but a comprehensive report analyzing the issuance plan. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it contains detailed financial and strategic analysis, not just a brief announcement or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2022-01-26 Chinese
关于未来三年（2022-2024年）股东分红回报规划（修订稿）
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the company's shareholder dividend return plan for the next three years (2022-2024). It references relevant regulatory guidelines and company bylaws, outlines principles and conditions for profit distribution, and details the decision-making process and disclosure requirements. The document is an announcement of a policy plan rather than a financial report or earnings release. It does not contain financial statements or results but rather a governance and policy disclosure related to dividends. Given the content and nature, this fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend policy and shareholder returns planning.
2022-01-26 Chinese
2022年度向特定对象发行股票募集资金使用可行性分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled '2022 年度向特定对象发行股票募集资金使用可行性分析报告（修订稿）' which translates to '2022 Annual Feasibility Analysis Report on the Use of Funds Raised by Private Placement of Shares (Revised Draft)'. It is issued by Jiangsu Deyuan Pharmaceutical Co., Ltd, a company listed on the Beijing Stock Exchange. The content details the company's plan to raise capital by issuing shares to specific investors, the intended use of the raised funds, feasibility analysis, project details, financial data of the target company, and related agreements. The document is a detailed report analyzing the use of funds raised through a specific share issuance, which fits the category of Capital/Financing Update (CAP). It is not an announcement of the issuance but a substantive report with financial data and project analysis. Therefore, the appropriate classification is CAP with high confidence.
2022-01-26 Chinese
2022年度向特定对象发行股票募集说明书（草案）
Capital/Financing Update Classification · 95% confidence The document is titled '2022 年度向特定对象发行股票募集说明书（草案）' which translates to '2022 Annual Private Placement Stock Issuance Prospectus (Draft)'. It is issued by Jiangsu Deyuan Pharmaceutical Co., Ltd. The content includes detailed information about the private placement stock issuance, including the background, purpose, issuance plan, shareholder structure, investment projects, pricing, lock-up periods, and risk disclosures. It also contains extensive financial and operational analysis related to the issuance. The document is lengthy (15,000 characters) and contains substantive financial and business data related to a capital raising event through a private placement of shares to specific investors. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an announcement of a report, nor a full annual or interim report, nor a regulatory filing or proxy statement. Therefore, the correct classification is CAP with high confidence.
2022-01-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.